biotech Archives - Vista Partners LLC | HomeVista Partners LLC

Healthcare’s Quiet Rally: Incyte, Pfizer & Eupraxia Put Some Spring in Wall Street’s Step – ( $EPRX $INCY $PFE $XBI )

by John F. Heerdink, Jr. 2 hours ago 109Views 0Likes

Health care may not have the meme-stock glamour of AI chips, but this spring the sector is quietly reminding investors why 'boring' can be beautiful. A trio of updates from Incyte (INCY), Pfizer (PFE) and Eupraxia Pharmaceuticals (NASDA: EPRX) is painting a…

Is Nanobiotix Building a Toll Road for Genetic Drugs? Early Preclinical Data Says “Maybe” -( $NBTX $JNJ $IBB $XBI )

by John F. Heerdink, Jr. 5 days ago 300Views 0Likes

Nanobiotix’s (NBTX) latest preclinical data suggest that its Nanoprimer technology may do for lipid nanoparticle (LNP) DNA immunotherapy what noise-cancelling headphones did for air travel: make a powerful experience markedly more tolerable. For investors watching the crossroad of oncology and genetic medicines,…

From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT )

by John F. Heerdink, Jr. April 20, 2026 119Views 0Likes

Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. As weight‑loss drugs…

Tribe Public Hosts Exclusive CEO Event: “Can Targeted Alpha Therapy Cure Cancer?”

by John F. Heerdink, Jr. April 13, 2026 136Views 0Likes

In the ever-evolving world of oncology innovation, a bold question is being asked: “Can Targeted Alpha Therapy Cure Cancer?” That’s the headline theme of Tribe Public’s next CEO Presentation and Q&A Webinar, scheduled for Tuesday, April 14, 2026, at 8 a.m. PT / 11 a.m.…

Acquired Taste: Why Big Pharma Can’t Stop Snacking on Venture‑Backed Biotechs -( $IBB $MRK $OTSKY $NVS $TERN $XBI )

by John F. Heerdink, Jr. April 2, 2026 277Views 0Likes

Big Pharma spent the week shopping again, snapping up a fresh crop of biotech and pharmaceutical names in deals that underscore one message: pipelines are the new gold, and the majors are still happily paying spot prices. From autoimmune bets to allergy…

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 430Views 0Likes

Yes indeed, Eupraxia Pharmaceutical's (NASDAQ: EPRX) EP-104 is quietly auditioning for a starring role in eosinophilic esophagitis—and for once, the gastroenterologist, the allergist, and the payer might actually clap at the same time. A Chronic Disease Finally Meets a Long-Term Plan Eosinophilic…

From Lab Bench to Stockpile Shelf: GeoVax’s GEO-MVA Aims for the Big Leagues -( $GOVX $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 258Views 0Likes

GeoVax’s (GOVX) latest update on its GEO-MVA program reads less like a small-cap press release and more like a biotech coming-of-age story, with Phase 3 now on the horizon and global health agencies finally circling the dance floor. For investors, the mpox/smallpox…

Merck’s Nearly $6 Billion Terns Buyout Deal Signals Big Pharma’s Next Act in Cancer—and Obesity? -( $MRK $TERN $LLY $NVS $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 500Views 0Likes

Merck (MRK) is preparing to spend nearly $6 billion in cash to acquire Terns Pharmaceuticals (TERN), a move that reads like a carefully scripted sequel to its Keytruda blockbuster rather than an impulsive spin-off. The price represents a premium to Terns’ roughly…

Is NAYA Therapeutics the Next Radiopharma Takeout? The Pipeline, the Board, and the Buzz – ( $AZN $BMY $IBB $LLY $NVS $XBI )

by John F. Heerdink, Jr. March 18, 2026 313Views 0Likes

NAYA Therapeutics (https://www.nayatx.com) is quietly trying to make “next‑gen radiopharma” sound less like sci‑fi and more like standard operating procedure—and its new board lineup reads like a who’s who of oncology, nuclear medicine, and biotech capital markets. A New Board for a…

Servier’s $2.5 Billion Bet on Rare Oncology: A Strategic Day One Biopharmaceuticals Play With a Pediatric Pulse -( $DAWN $XBI $IBB )

by John F. Heerdink, Jr. March 6, 2026 951Views 0Likes

French pharmaceutical group Servier has quietly become one of the most methodical players in oncology—and its latest move underscores that reputation. The company announced a definitive agreement to acquire Day One Biopharmaceuticals (Nasdaq: DAWN) for $21.50 per share in cash, valuing the…

Tag: biotech

Healthcare’s Quiet Rally: Incyte, Pfizer & Eupraxia Put Some Spring in Wall Street’s Step – ( $EPRX $INCY $PFE $XBI )

Is Nanobiotix Building a Toll Road for Genetic Drugs? Early Preclinical Data Says “Maybe” -( $NBTX $JNJ $IBB $XBI )

From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT )

Tribe Public Hosts Exclusive CEO Event: “Can Targeted Alpha Therapy Cure Cancer?”

Acquired Taste: Why Big Pharma Can’t Stop Snacking on Venture‑Backed Biotechs -( $IBB $MRK $OTSKY $NVS $TERN $XBI )

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

From Lab Bench to Stockpile Shelf: GeoVax’s GEO-MVA Aims for the Big Leagues -( $GOVX $IBB $XBI )

Merck’s Nearly $6 Billion Terns Buyout Deal Signals Big Pharma’s Next Act in Cancer—and Obesity? -( $MRK $TERN $LLY $NVS $IBB $XBI )

Is NAYA Therapeutics the Next Radiopharma Takeout? The Pipeline, the Board, and the Buzz – ( $AZN $BMY $IBB $LLY $NVS $XBI )

Servier’s $2.5 Billion Bet on Rare Oncology: A Strategic Day One Biopharmaceuticals Play With a Pediatric Pulse -( $DAWN $XBI $IBB )

Your Guide To Staying Informed In The Markets